DE60238490D1 - Verwendung von humanem choriongonadotropin (hcg) und luteinisierendem hormon (lh) zur regulierten hyperstimulation der eierstöcke - Google Patents

Verwendung von humanem choriongonadotropin (hcg) und luteinisierendem hormon (lh) zur regulierten hyperstimulation der eierstöcke

Info

Publication number
DE60238490D1
DE60238490D1 DE60238490T DE60238490T DE60238490D1 DE 60238490 D1 DE60238490 D1 DE 60238490D1 DE 60238490 T DE60238490 T DE 60238490T DE 60238490 T DE60238490 T DE 60238490T DE 60238490 D1 DE60238490 D1 DE 60238490D1
Authority
DE
Germany
Prior art keywords
eggstuffs
hyperstimulation
hcg
regulated
luteinizing hormone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60238490T
Other languages
English (en)
Inventor
Yves Menezo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Merck Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8182262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60238490(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Serono SA filed Critical Merck Serono SA
Application granted granted Critical
Publication of DE60238490D1 publication Critical patent/DE60238490D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/11—Gonadotropin; related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/13—Luteinizing hormone-releasing hormone; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE60238490T 2001-09-12 2002-09-12 Verwendung von humanem choriongonadotropin (hcg) und luteinisierendem hormon (lh) zur regulierten hyperstimulation der eierstöcke Expired - Lifetime DE60238490D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01307758 2001-09-12
PCT/GB2002/004167 WO2003022303A2 (en) 2001-09-12 2002-09-12 Use of hcg and lh in controlled ovarian hyperstimulation

Publications (1)

Publication Number Publication Date
DE60238490D1 true DE60238490D1 (de) 2011-01-13

Family

ID=8182262

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60238490T Expired - Lifetime DE60238490D1 (de) 2001-09-12 2002-09-12 Verwendung von humanem choriongonadotropin (hcg) und luteinisierendem hormon (lh) zur regulierten hyperstimulation der eierstöcke

Country Status (27)

Country Link
US (1) US7402558B2 (de)
EP (1) EP1425033B1 (de)
JP (1) JP2005501919A (de)
KR (1) KR20040032952A (de)
CN (1) CN100376289C (de)
AR (1) AR036593A1 (de)
AT (1) ATE489964T1 (de)
BR (1) BR0212447A (de)
CA (1) CA2457851A1 (de)
CY (1) CY1110991T1 (de)
DE (1) DE60238490D1 (de)
DK (1) DK1425033T3 (de)
EA (1) EA009279B1 (de)
ES (1) ES2356895T3 (de)
HK (1) HK1067865A1 (de)
HR (1) HRP20040086A2 (de)
IL (1) IL160782A0 (de)
ME (1) MEP38708A (de)
MX (1) MXPA04002257A (de)
NO (1) NO327153B1 (de)
PL (1) PL369021A1 (de)
PT (1) PT1425033E (de)
SI (1) SI1425033T1 (de)
UA (1) UA82052C2 (de)
WO (1) WO2003022303A2 (de)
YU (1) YU21104A (de)
ZA (1) ZA200400781B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
GB0723882D0 (en) * 2007-12-07 2008-01-23 Univ Leicester Methods for the detection of a threatened miscarriage
AU2012286048A1 (en) 2011-07-18 2014-02-20 Arts Biologics A/S Long acting luteinizing hormone (LH) compound
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
ES2716862T3 (es) * 2014-12-22 2019-06-17 Ferring Bv Terapia con antagonistas del receptor de oxitocina en la fase lútea para la implantación y embarazo en mujeres que se someten a tecnologías de reproducción asistida
FI3261661T3 (fi) 2015-02-26 2024-01-15 Ferring Bv Menotropiini hedelmättömyyden hoitamiseksi
US11185569B2 (en) * 2016-05-04 2021-11-30 University Of Cincinnati ActRIIB:Fc to treat infertility in females
TWI846743B (zh) * 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
CN110041436A (zh) * 2019-04-28 2019-07-23 广州威生医药科技有限公司 长效重组fsh融合蛋白在母猪批次化生产中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4589402A (en) 1984-07-26 1986-05-20 Serono Laboratories, Inc. Method of in vitro fertilization
US5705478A (en) * 1989-02-21 1998-01-06 Washington University Covalently linked β subunits of the glycoprotein hormones as antagonists
FR2744367B1 (fr) * 1996-02-02 1999-07-09 Emperaire Jean Claude Medicaments pour le declenchement de l'ovulation
WO1998058657A1 (en) * 1997-06-20 1998-12-30 Akzo Nobel N.V. Gonadotropin releasing hormone antagonist
ZA987497B (en) * 1997-09-08 1999-02-23 Akzo Nobel Nv Expression of gonadotropins in dictyostelium
US6090848A (en) * 1997-12-01 2000-07-18 Sigma-Tau Healthscience S.P.A. Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
KR20010093280A (ko) * 1999-02-24 2001-10-27 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 불임증 치료
SI1176976T2 (sl) * 1999-05-07 2015-12-31 Merck Serono Sa Uporaba LH, dajanega v srednji ali pozni folikularni fazi, za zdravljenje anovulatornih žensk
PL211113B1 (pl) * 2000-01-27 2012-04-30 Serono Lab Zastosowanie FSH do leczenia bezpłodności
US6953774B2 (en) * 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation

Also Published As

Publication number Publication date
MXPA04002257A (es) 2004-07-23
CY1110991T1 (el) 2015-06-11
MEP38708A (en) 2011-02-10
YU21104A (sh) 2006-08-17
JP2005501919A (ja) 2005-01-20
US7402558B2 (en) 2008-07-22
DK1425033T3 (da) 2011-01-10
CN1553810A (zh) 2004-12-08
WO2003022303A3 (en) 2003-12-18
HRP20040086A2 (en) 2004-12-31
NO327153B1 (no) 2009-05-04
PT1425033E (pt) 2010-12-29
CA2457851A1 (en) 2003-03-20
SI1425033T1 (sl) 2011-01-31
ES2356895T3 (es) 2011-04-14
WO2003022303A2 (en) 2003-03-20
CN100376289C (zh) 2008-03-26
BR0212447A (pt) 2004-08-17
NO20040962L (no) 2004-03-05
AR036593A1 (es) 2004-09-22
HK1067865A1 (en) 2005-04-22
EA200400426A1 (ru) 2004-08-26
ZA200400781B (en) 2005-04-26
EP1425033B1 (de) 2010-12-01
ATE489964T1 (de) 2010-12-15
EP1425033A2 (de) 2004-06-09
EA009279B1 (ru) 2007-12-28
PL369021A1 (en) 2005-04-18
UA82052C2 (uk) 2008-03-11
US20050020489A1 (en) 2005-01-27
IL160782A0 (en) 2004-08-31
KR20040032952A (ko) 2004-04-17

Similar Documents

Publication Publication Date Title
DE60222671D1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
DE60034725D1 (de) Mehrrichtungsschalter und seine Verwendung
DE60204548D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
DE60140377D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
DE60237342D1 (de) Elektrooptische Vorrichtung und elektronisches Gerät
DE69942663D1 (de) Zusammenfügen von Sprachschnittstellen zur gleichzeitigen Benützung von Vorrichtungen und Anwendungen
EE200300485A (et) Tiohüdantoinid ja nende kasutamine diabeedi raviks
DE50305570D1 (de) Einrichtung zur erzeugung von terahertz-strahlung sowie halbleiterbauelement
ATE331522T1 (de) Zusammensetzung zur behandlung von atemwegs- und hauterkrankungen mit mindestens einem leukotrienantagonist und mindestens einem antihistaminikum
DE60227300D1 (de) Strukturen von anschlusselementen und anzuschliessende komponente
ATE349428T1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE69927971D1 (de) Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c
DE60202677D1 (de) Implantierbare medizinische vorrichtung mit kontrollierter freigabe von gasförmigen mitteln
DE60101853D1 (de) Schaltungsunabhängige transformation von sensorkonfigurationen zur klassifizierung von personen
DE60209844D1 (de) Parkassistent und seine Vorgehensweise
DE50010833D1 (de) Pharmazeutisches präparat enthaltend diamorphin und vitamin e seine verwendung zur behandlung der opiatsucht
DE60238206D1 (de) Frequenz- und amplitudenapodisierung von wandlern
DE60238490D1 (de) Verwendung von humanem choriongonadotropin (hcg) und luteinisierendem hormon (lh) zur regulierten hyperstimulation der eierstöcke
ATE420866T1 (de) 4-(phenylpiperazinylmethyl) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
DE60137929D1 (de) Verwendung von lanthan bei der behandlung von knochenerkrankungen
DE69936514D1 (de) Heliomycin-kodierendes gen und seine verwendung
DE60321129D1 (de) Rekombinantes herpesvirus aus truthahn und verwendung davon
DE60014621D1 (de) Zentrifugationsvorrichtung und verwendung dieser vorrichtung
DE60330262D1 (de) Vorrichtung zur erleichterung und authentifizierung von transaktionen
DE60220871D1 (de) Optimalisierte Echtzeit-Druckmaskenüberprüfung und optimalisiertes Druckelementendatensystem zur Vermeidung der Verwendung von fehlerhaften Elementen